文献速递乳腺癌放疗

老年低危乳腺癌保乳术后辅助放疗、内分泌治疗或两者联合:基于人群研究结果

Adjuvant breast radiotherapy, endocrine therapy, or both after breast conserving surgery in older women with low-risk breast cancer: Results from a population-based study.
PubMed 文献 · Radiother Oncol · 2020-09-14

该基于人群研究纳入2005至2015年≥70岁、T1-2N0、ER阳性、Her-2/neu阴性早期乳腺癌保乳术后患者1166例,中位随访76.5个月。与单纯保乳相比,单纯放疗、单纯内分泌治疗及放疗+内分泌治疗均显著改善无复发生存,三组间无复发生存和乳腺癌特异生存无差异。合并症评分升高与总生存降低独立相关。

要点

  • 老年低危早期乳腺癌保乳术后,单纯放疗是无复发生存和乳腺癌特异生存方面不劣于内分泌治疗或联合治疗的合理选择。
  • 合并症评分升高(0 vs 1;0 vs ≥2)与总生存降低独立相关,但不影响无复发生存或乳腺癌特异生存。
  • 不足60%患者完成5年内分泌治疗,提示该人群内分泌治疗依从性有限。

核心结论

  • 对于生物学行为良好的老年早期乳腺癌患者,单纯辅助放疗是内分泌治疗或放疗+内分泌治疗的合理替代方案。
  • 单纯放疗、单纯内分泌治疗及放疗+内分泌治疗三组间无复发生存和乳腺癌特异生存无差异。
  • 合并症独立关联总生存降低,但不影响无复发生存或乳腺癌特异生存。

研究设计与样本

  • 基于人群研究,纳入2005至2015年≥70岁、T1-2N0、ER阳性、Her-2/neu阴性早期乳腺癌保乳术后接受辅助治疗(单纯放疗、单纯内分泌治疗或放疗+内分泌治疗)的全部女性。
  • 共识别1166例患者,中位随访76.5个月;收集治疗细节并计算Charlson合并症指数(CCI)。
  • 主要结局指标为无复发生存(RFS)、总生存(OS)和乳腺癌特异生存(BCSS)。

主要发现

  • 辅助治疗分布:单纯保乳130例(11%)、单纯放疗378例(32.5%)、单纯内分泌治疗161例(14%)、放疗+内分泌治疗497例(42.5%)。
  • 不足60%的女性完成5年内分泌治疗。
  • 与单纯保乳相比,单纯放疗显著改善RFS(HR=0.174;p<0.001),单纯内分泌治疗(HR=0.414;p=0.007)和放疗+内分泌治疗(HR=0.236;p<0.001)亦相似改善RFS。
  • OS的决定因素包括年龄、肿瘤分级、合并症和辅助治疗。
  • 合并症评分升高(0 vs 1;0 vs ≥2)与OS降低相关(HR=1.40;p=0.013和HR=1.98;p<0.001),对RFS或BCSS无影响。

关键数值与推荐

  • 与单纯保乳相比,单纯放疗改善RFS的HR=0.174(p<0.001)。
  • 与单纯保乳相比,单纯内分泌治疗改善RFS的HR=0.414(p=0.007)。
  • 与单纯保乳相比,放疗+内分泌治疗改善RFS的HR=0.236(p<0.001)。
  • 合并症评分0 vs 1与OS降低相关(HR=1.40;p=0.013);0 vs ≥2与OS降低相关(HR=1.98;p<0.001)。

临床怎么用

  • 对于≥70岁、T1-2N0、ER阳性、Her-2/neu阴性早期乳腺癌保乳术后患者,可考虑单纯辅助放疗作为内分泌治疗或放疗+内分泌治疗的替代方案。
  • 制定辅助治疗决策时应评估合并症(CCI),合并症评分升高提示总生存可能降低。
  • 需关注老年患者内分泌治疗依从性,本研究中不足60%完成5年内分泌治疗。

局限性

  • 原文未报告研究局限性相关内容。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: The relative benefit of adjuvant radiotherapy (RT) alone in older women with low-risk early breast cancer (EBC) remains unclear. It is hypothesized that adjuvant RT-alone can improve outcomes of older patients with low-risk EBC, similar to endocrine therapy (ET) alone or combination of RT + ET. METHODS: In this population based study, we identified all women aged ≥70 with T1-2, N0, ER+ve, Her-2/neu-ve EBC treated with breast conserving surgery (BCS), followed by adjuvant treatments (RT-alone, ET-alone, or RT + ET combination) from 2005 to 2015. Primary outcome measures were recurrence-free survival (RFS), overall survival (OS), and breast cancer specific survival (BCSS). Treatment details were collected and Charlson Comorbidity Index (CCI) was calculated. RESULTS: A total of 1166 patients were identified. Median follow-up was 76.5 months. Adjuvant treatments: BCS only 130 (11%), RT 378 (32.5%), ET 161 (14%), and RT + ET 497 (42.5%). Less than 60% of women completed 5-years of ET. Compared to BCS alone, RT resulted in significant improvement in RFS (HR = 0.174; p < 0.001), similar to ET (HR = 0.414; p = 0.007) and RT + ET (HR = 0.236; p < 0.001). Determinants of OS were age, tumor grade, comorbidities, and adjuvant therapy. Increased comorbidity scores (0 vs. 1; 0 vs. ≥2) were associated with reduced OS (HR = 1.40; p = 0.013 and HR = 1.98; p < 0.001), without impact on RFS or BCSS. CONCLUSIONS: Adjuvant RT-alone is a reasonable alternative to ET or RT + ET for older women with biologically favorable EBC. No difference in RFS or BCSS was noted between RT, ET, and RT + ET. Comorbidity was independently associated with reduced overall survival.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Joseph K, Zebak S, Alba V, et al. Adjuvant breast radiotherapy, endocrine therapy, or both after breast conserving surgery in older women with low-risk breast cancer: Results from a population-based study. Radiother Oncol. 2020. PMID: 32941956. doi:10.1016/j.radonc.2020.09.017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。